What changed
$NVO — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $13.6B | EPS $6.63 vs $6.96 🔴
💡 Consensus sees slowing growth and margin pressure, pricing the stock at a ~6.7× P/E on depressed EPS. Our variant view is that the miss is transitory (e.g., higher R&D, acquisition costs, supply timing) and that normalized EPS is $8–$9, implying a fair P/E of 12–15×, or $96–$135 per share. The market is wrong by over‑discounting a one‑time event.
📉 Reward/risk: 2.5:1
🏢 Business Quality: 8/10 - Wide moat from entrenched GLP‑1 franchise, strong pipeline (oral semaglutide, next‑gen obesity), high switching costs, and global scale. Margin risk from competition and patent expirations is real but priced in.
📊 Valuation: cheap — P/E 6.66 (vs. 5‑year average 18× and pharma peer median 14×); EV/EBITDA unavailable but likely deeply discounted.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/NVO0615